GUIDE-IT is a prospective , randomized , controlled , unblinded , multicenter clinical trial designed to randomize approximately @,@ high-risk subjects with systolic HF ( left ventricular ejection fraction@ % ) to either usual care ( optimized guideline-recommended therapy ) or a strategy of adjusting therapy with the goal of achieving and maintaining a target NT-proBNP level of < @,@ pg/ml .